Overview
Metastatic carcinoma involving the fundus of the stomach, particularly signet ring cell carcinoma (SRCC), presents a significant clinical challenge due to its aggressive nature and advanced stage at presentation. This condition often complicates diagnosis and management, necessitating a multidisciplinary approach that integrates surgical, chemotherapeutic, and supportive care strategies. Epidemiological data from Slovakia indicate that a substantial proportion of gastric cancer (GC) patients are diagnosed at advanced stages (III and IV), underscoring the importance of early detection and aggressive intervention. Demographic factors such as older age and female gender are also recognized risk factors for gastric SRCC, guiding patient stratification and tailored therapeutic approaches.
Epidemiology
The epidemiology of metastatic gastric carcinoma, particularly in regions like Slovakia, highlights the critical issue of late-stage diagnosis. Studies show that approximately 62% of GC patients in Slovakia are diagnosed at stages III and IV, reflecting a common pattern of advanced presentation [PMID:40251306]. This advanced stage at diagnosis significantly impacts treatment options and overall prognosis. Additionally, risk factors for gastric SRCC, including older age and female gender, provide crucial demographic context for clinicians to identify high-risk populations [PMID:31448584]. Understanding these epidemiological trends is essential for developing targeted screening programs and early intervention strategies to improve patient outcomes.
Clinical Presentation
Patients with metastatic carcinoma in the fundus of the stomach, especially those with SRCC, often present with a constellation of symptoms reflecting the rapid growth and diffuse infiltration characteristic of this malignancy. Clinically, patients may experience nonspecific symptoms such as abdominal pain, weight loss, and fatigue, which can complicate early diagnosis [PMID:31448584]. More specific presentations can include severe abdominal and lumbar pain, indicative of tumor burden and potential complications like bowel obstruction or visceral irritation. A notable case report illustrates a patient presenting with tachycardia, severe abdominal pain, and significant metabolic acidosis (lactate 9.7 mmol/L) shortly after initiating chemotherapy, suggesting acute complications such as thrombotic events [PMID:26917797]. These acute presentations underscore the need for vigilant monitoring and prompt intervention to manage complications effectively.
Diagnosis
Accurate diagnosis of metastatic gastric carcinoma, particularly SRCC, is pivotal for guiding appropriate treatment strategies. Histological confirmation remains the gold standard, distinguishing SRCC from other gastric cancer subtypes through microscopic examination of tissue samples [PMID:31448584]. This distinction is crucial as it influences the choice of systemic therapies and surgical interventions. Diagnostic imaging modalities such as abdominal ultrasound and percutaneous liver biopsy play a vital role in identifying metastatic spread, as evidenced by a case where recurrence was detected and confirmed through these methods [PMID:28625333]. Identifying specific metastatic sites and the extent of disease through comprehensive imaging and biopsy can significantly enhance prognostic accuracy and inform tailored therapeutic plans.
Management
The management of metastatic gastric carcinoma, especially SRCC, involves a multifaceted approach combining systemic therapy and surgical interventions tailored to patient-specific factors. Conversion surgery, particularly in patients categorized as potentially resectable or marginally resectable for metastatic disease (categories 2 and some category 3), has shown promising outcomes, with median overall survival reaching up to 15 months and 5-year survival rates of 24% [PMID:40251306]. Palliative gastrectomy combined with adjuvant chemotherapy has emerged as a strategy that can improve survival in stage IV gastric SRCC patients, contrasting with earlier studies that showed limited benefits from gastrectomy alone [PMID:31448584]. However, the decision to proceed with surgery must weigh the potential benefits against the risks, including significant morbidity and mortality rates observed in some studies (34.5% morbidity and 9% mortality in one cohort) [PMID:20941968].
Chemotherapy regimens, such as the EOX protocol (epirubicin, oxaliplatin, capecitabine), are commonly employed but require careful monitoring due to potential severe complications like arterial thrombosis, as highlighted by a case report where a patient developed life-threatening thrombosis shortly after initiating treatment [PMID:26917797]. In such cases, prophylactic anticoagulation with agents like enoxaparin can be crucial for preventing recurrence and managing thrombotic events. Successful surgical interventions, such as extended right hemihepatectomy following recurrence, have demonstrated prolonged disease-free survival (up to 47 months) and overall survival (13 years from initial treatment) in select patients [PMID:28625333]. These outcomes emphasize the potential for curative intent in carefully selected patients, even in advanced stages.
Complications
Metastatic gastric carcinoma, particularly SRCC, is associated with a range of serious complications that can significantly impact patient outcomes. Acute complications include severe metabolic derangements, such as metabolic acidosis with elevated lactate levels, reflecting systemic toxicity and organ dysfunction [PMID:26917797]. Thrombotic events, particularly arterial thrombosis, are another critical complication that can arise rapidly following chemotherapy initiation, necessitating immediate anticoagulation therapy to prevent further vascular damage [PMID:26917797]. Surgical interventions, while potentially curative, carry their own set of risks, including significant morbidity (34.5%) and mortality (9%) in advanced cases [PMID:20941968]. These complications underscore the importance of multidisciplinary care, including hematology and intensive care support, to manage acute issues effectively and improve patient survival.
Prognosis & Follow-up
The prognosis for patients with metastatic gastric carcinoma, especially SRCC, is generally poor, with multi-organ metastasis being a significant predictor of poorer outcomes [PMID:40251306]. Gastric SRCC is characterized by higher metastatic rates and lower overall survival compared to non-SRCC gastric cancers, highlighting the need for aggressive and comprehensive treatment strategies [PMID:31448584]. Despite these challenges, select cases demonstrate prolonged survival with meticulous patient selection and aggressive interventions, such as extended surgical resections, achieving survival rates up to 13 years [PMID:28625333]. Regular follow-up is essential, incorporating imaging studies and biomarker assessments to monitor disease progression and detect recurrence early. The mean survival times reported in various studies, ranging from 6.4 months with chemotherapy alone to 17.8 months with palliative gastrectomy plus adjuvant therapy, underscore the variability in outcomes and the importance of individualized treatment plans [PMID:20941968].
Key Recommendations
These recommendations aim to optimize patient care by leveraging current evidence while acknowledging the need for individualized treatment plans tailored to each patient's clinical scenario.
References
1 Palaj J, Kečkéš Š, Marek V, Dyttert D, Sabol M, Durdík Š et al.. Single centre experience with conversion surgery for advanced and metastatic gastric cancer in Slovakia. Scientific reports 2025. link 2 Shi T, Song X, Liu Q, Yang Y, Yu L, Liu B et al.. Survival benefit of palliative gastrectomy followed by chemotherapy in stage IV gastric signet ring cell carcinoma patients: A large population-based study. Cancer medicine 2019. link 3 Boon IS, Boon CS. In the nick of time: arterial thrombosis on starting combination chemotherapy in metastatic gastric adenocarcinoma. BMJ case reports 2016. link 4 Polkowska-Pruszyńska B, Rawicz-Pruszyński K, Ciseł B, Sitarz R, Polkowska G, Krupski W et al.. Liver metastases from gastric carcinoma: A Case report and review of the literature. Current problems in cancer 2017. link 5 Lupaşcu C, Andronic D, Ursulescu C, Vasiluţă C, Raileanu G, Georgescu St et al.. Palliative gastrectomy in patients with stage IV gastric cancer--our recent experience. Chirurgia (Bucharest, Romania : 1990) 2010. link